Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?
Trends in Cancer · 2025
DOI: 10.1016/j.trecan.2025.05.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Cancer, 2025. Verfasst von John B Haanen. Beteiligte Einrichtung: Division of Medical Oncology, NKI, Amsterdam, Netherlands; Department of Medical Oncology, LUMC, Leiden, Netherlands; Oncology Service, CHUV, Lausann…. Hauptthemen laut MEDLINE: Lymphocytes, Tumor-Infiltrating, Gastrointestinal Neoplasms, Immunotherapy, Adoptive. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A recent study published in Nature Medicine shows that adoptive cell therapy using neoantigen-selected tumor-infiltrating lymphocytes (TIL) is feasible in refractory metastatic gastrointestinal (GI) cancers, showing durable responses, especially when combined with anti-PD-1. Despite low tumor mutational burden (TMB), enriched neoantigen-reactive TIL improved objective response rates (ORR), highlighting the role of the tumor microenvironment and supporting further clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, NKI, Amsterdam, Netherlands; Department of Medical Oncology, LUMC, Leiden, Netherlands; Oncology Service, CHUV, Lausanne, Switzerland. Electronic address: j.haanen@nki.nl.
Zitieren
APA
Haanen, J. B. (2025). Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?. Trends in Cancer. https://doi.org/10.1016/j.trecan.2025.05.004
Vancouver
Haanen JB. Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?. Trends in Cancer. 2025. doi:10.1016/j.trecan.2025.05.004
BibTeX
@article{Haanen2025,
author = {Haanen, John B},
title = {Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?},
journal = {Trends in Cancer},
year = {2025},
doi = {10.1016/j.trecan.2025.05.004}
}
EUVIMED